Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector

Molecular Therapy

Volumn 3, Issue 1, 2001, Pages 78-87

  Sawai, Nobukuni ^a   Zhou, Sheng ^a   Vanin, Elio F ^a   Houghton, Peter ^a   Brent, Thomas P ^a   Sorrentino, Brian P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Bone marrow transplantation; Gene therapy; Hematopoietic stem cells; Methylguanine DNA methyltransferase; O6 benzylguanine; Retroviral vector; Temozolomide

Indexed keywords

6 O BENZYLGUANINE; GREEN FLUORESCENT PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CELL COUNT; CELL LINEAGE; CELL PROTECTION; CELL SELECTION; CONTROLLED STUDY; DILUTION; DNA METHYLATION; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; DRUG TOXICITY; ENZYME ACTIVITY; EVALUATION; FEMALE; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PROTECTION; RECEPTOR GENE; RETROVIRUS;

ANIMALIA; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0034990304     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0223     Document Type: Article

References (60)

1. Drug resistance gene therapy
2. The hematopoietic system as a target for gene therapy
3. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1
4. Transfer and expression of the human multiple drug resistance gene into live mice
5. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells
6. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit
7. Dominant selection of hematopoietic progenitor cells with retroviral MDR1 co-expression vectors
8. In vivo selection of retrovirally transduced hematopoietic stem cells
9. A gene transfer strategy for making bone marrow cells resistant to trimetrexate
10. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow
11. Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase
12. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea
13. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent
14. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo
15. Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity
16. Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea
17. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide
18. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy
19. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation
20. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients
21. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy
22. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
23. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells
24. O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea
25. Prolonged depletion of O6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro
26. Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate
27. O6-Benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair
28. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma
29. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine
30. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: Implications for drug resistance gene therapy
31. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme
32. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
33. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children's Cancer Group
34. O6-Benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow
35. Chemoprotective gene transfer. I. Transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro
36. Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice
37. 6-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection
38. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo
39. Utilization of the green fluorescent protein gene as a marker to identify and track genetically-modified hematopoietic cells
40. High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34(+) cells
41. A safe packaging line for gene transfer: Separating viral genes on two different plasmids
42. Versatile retroviral vectors for potential use in gene therapy
43. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis
44. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene
45. Murine retroviruses use at least six different receptors for entry into Mus dunni cells
46. Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine
47. Sustained high-level reconstitution of the hematopoietic system by preselected hematopoietic cells expressing a transduced cell-surface antigen
48. Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy
49. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents
50. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea
51. Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: Possible significance in nitrosourea therapy
52. O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts
53. O6-Benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide
54. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability
55. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor
56. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease
57. Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning
58. Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells
59. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells
60. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase